UBX

Ongoing Fitness Trends Are Driving the Growth of the Health and Fitness Club Market Globally at a CAGR of 9.2% Through 2034

Retrieved on: 
Monday, March 25, 2024
Health, Obesity, Anytime Fitness, Growth, Sample, Digital, Indian stock exchange, Associate, UBX, Social media, Artificial intelligence, Life, Machine learning, Pet industry

According to Future Market Insights reports, the health and fitness club market is envisioned to reach US$ 302 billion by 2034, growing from $124.7 billion in 2024.

Key Points: 
  • According to Future Market Insights reports, the health and fitness club market is envisioned to reach US$ 302 billion by 2034, growing from $124.7 billion in 2024.
  • The rise of boutique fitness studios, increasing awareness about health concerns, and the corporatization of jobs are benchmarks in driving the growth of the fitness market.
  • The health and fitness club market in the United Kingdom is predicted to rise by a remarkable 10.3% CAGR through 2034.
  • The health and fitness club market in the United States is estimated to rise at a whopping 9.6% CAGR through 2034.

Ongoing Fitness Trends Are Driving the Growth of the Health and Fitness Club Market Globally at a CAGR of 9.2% Through 2034

Retrieved on: 
Monday, March 25, 2024
Health, Obesity, Anytime Fitness, Growth, Sample, Digital, Indian stock exchange, Associate, UBX, Social media, Artificial intelligence, Life, Machine learning, Pet industry

According to Future Market Insights reports, the health and fitness club market is envisioned to reach US$ 302 billion by 2034, growing from $124.7 billion in 2024.

Key Points: 
  • According to Future Market Insights reports, the health and fitness club market is envisioned to reach US$ 302 billion by 2034, growing from $124.7 billion in 2024.
  • The rise of boutique fitness studios, increasing awareness about health concerns, and the corporatization of jobs are benchmarks in driving the growth of the fitness market.
  • The health and fitness club market in the United Kingdom is predicted to rise by a remarkable 10.3% CAGR through 2034.
  • The health and fitness club market in the United States is estimated to rise at a whopping 9.6% CAGR through 2034.

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Paper, SAN, Cell, Research, VEGF, Therapy, Ageing, Environment, Patient, Diabetic retinopathy, Hyperglycemia, Unity Biotechnology, Retina, Homeostasis, Visual acuity, UBX, Cellular senescence, Diabetes, Endothelium, DME, University, Eye, Metalloproteinase, Nature Medicine, Université de Montréal, Pharmaceutical industry

Sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye.

Key Points: 
  • Sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye.
  • This can lead to fluid accumulation and retinal thickening – a key feature of DME.
  • They demonstrated that these senescent cells contribute to loss of barrier function, which can cause leaky blood vessels.
  • This research further supports the potential for senolytic medicines to address the significant unmet need with current standard of care.”

u-blox introduces new LTE-M modules with integrated GNSS to boost industrial connectivity

Retrieved on: 
Tuesday, February 6, 2024
MCU, App Store (iOS/iPadOS), R52, TTFF, DBm, UBX, Software, GNSS, Communication, Recycling, LTE-M, Mobile phone

These modules, designed for industrial applications, are based on the u-blox UBX-R52 cellular chip and are tailored for integrated and concurrent positioning and wireless communication needs.

Key Points: 
  • These modules, designed for industrial applications, are based on the u-blox UBX-R52 cellular chip and are tailored for integrated and concurrent positioning and wireless communication needs.
  • The new u-blox R52 series also introduces a new combo module designed to offer simultaneous GNSS and cellular connectivity – an important attribute for applications requiring continuous or cyclic tracking.
  • The u-blox SARA-R520M10 combo module comes equipped with an integrated u-blox M10 GNSS receiver and ensures concurrent tracking with low-power consumption, better TTFF, and improved RF sensitivity.
  • Many LTE-M modules only offer an RF output power of 20-21 dBm, whereas the new R52 series offers 23 dBm, ensuring stable connectivity in challenging coverage conditions.

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Unity Biotechnology, DME, Diabetic retinopathy, SAN, Standard of care, CST, Ageing, Patient, UBX, Safety, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325 (foselutoclax), a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema (DME).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325 (foselutoclax), a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema (DME).
  • “Many patients with DME have poor vision despite frequent anti-VEGF injections and there is an urgent need to develop new treatment options for such patients,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY.
  • “There has been great interest from the physician community in the therapeutic potential of UBX1325, which is based on a novel senolytic mechanism of action, and we are excited to have dosed our first patients in the ASPIRE study.
  • Secondary endpoints will include change in BCVA over time, and central subfield thickness (CST) change from baseline to week 24.

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Monday, November 13, 2023
Research, Safety, SAN, Visual acuity, Diabetic retinopathy, Depreciation, Patient, DME, Biotechnology, Therapy, UBX, Ageing, AMD, Operating cost, Unity Biotechnology, Pharmaceutical industry, Cryptocurrency

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023.
  • It is expected to enroll about 40 subjects, with 16-week data expected in the fourth quarter of 2024 and 24-week data expected in the first quarter of 2025.
  • Operating loss for the three months ended September 30, 2023 was $15.3 million compared to $13.7 million for the three months ended September 30, 2022.
  • Cash used in operations during the nine quarters of 2023 was $29.5 million compared to $40.7 million for the nine quarters of 2022.

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds

Retrieved on: 
Friday, November 10, 2023
Sale, SAN, Security (finance), Form, Exercise, Peer-to-peer file sharing, Clinical trial, Biotechnology, Therapy, UBX, Ageing, Unity Biotechnology

The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No.

Key Points: 
  • The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No.
  • The gross proceeds to UNITY from the exercise of the warrants are expected to be approximately $4.38 million, prior to deducting placement agent fees and offering expenses.
  • In consideration for the immediate exercise of the warrants for cash, UNITY will issue new unregistered warrants to purchase up to 2,143,000 shares of common stock.
  • UNITY has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

UBX Launches a Revolutionary Innovation in Boutique Fitness: “Extended Access”

Retrieved on: 
Wednesday, November 15, 2023
Fitness & Nutrition, Health, Sports, Boxing, Creed III, Combat sport, Warner Bros. Pictures, UBX, Multimedia, Extended Access Control, Universal, Sport, Partnership, Access, Retail

View the full release here: https://www.businesswire.com/news/home/20231113948322/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231113948322/en/
    UBX members can now enter their UBX gym outside of staffed hours with "Extended Access" (Photo: Business Wire)
    “Extended Access” grants UBX members unprecedented freedom to train outside traditional hours, transcending the constraints of regular boutique gym schedules.
  • This feature not only enhances member experience but also significantly bolsters member retention and franchise revenue through increased yield, conversions, capacity and demand.
  • The “Coaching Screens” integral to UBX gyms provide members with a seamless workout experience at any time.
  • Embracing the "convenience economy," UBX stands at the forefront of boutique fitness by delivering the most accessible and flexible training options to its members.

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

Retrieved on: 
Wednesday, September 27, 2023
UNITY, Colic flexures, Biotechnology, Therapy, Anti-VEGF, DME, AMD, Ageing, Diabetic retinopathy, Part, Inflammation, Unity Biotechnology, Patient, Endophthalmitis, UBX, Visual acuity, Safety, Disease, Birth control, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced results from Part B of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy.

Key Points: 
  • Patients switched from every 8-week aflibercept to a combination of aflibercept and UBX1325 at week 24 maintained vision gains achieved with aflibercept alone through week 48.
  • “The ENVISION study shows that patients with wet AMD who switch from anti-VEGF to UBX1325 can maintain visual acuity with a significant reduction in anti-VEGF treatment burden.
  • Patients with more severe disease may benefit from a combination of aflibercept and UBX1325,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY.
  • UNITY has initiated a Phase 2b study in patients with diabetic macular edema and expects to randomize the first patient in that study in Q4 2023.

UBX Boxing + Strength launches in Japan - on track for 500 locations in the next 5 years

Retrieved on: 
Monday, September 11, 2023
Sport, Partnership, Boxing, Marketing, Combat sport, Walking the Floor Over You (box set), UBX, Bank, Environment, Martial arts, Film industry

Together with Prova Group, UBX is set to open a minimum of 145 locations in Japan over the next 10 years.

Key Points: 
  • Together with Prova Group, UBX is set to open a minimum of 145 locations in Japan over the next 10 years.
  • UBX offers a one-of-a-kind fitness experience by combining boxing and strength training in a 12-round circuit.
  • By offering unparalleled flexibility and accessibility, UBX has quickly become the world's leading boxing and strength provider.
  • With its exceptional growth trajectory and unwavering dedication, UBX is poised to become the go-to destination for boxing enthusiasts worldwide.